Sedgwick J B, Busse W W
Department of Medicine, University of Wisconsin, Madison, USA.
Ann Allergy Asthma Immunol. 1997 Jun;78(6):581-5. doi: 10.1016/S1081-1206(10)63219-X.
Cetirizine is an antihistamine that inhibits in vivo eosinophil influx into the inflamed airways following allergen challenge, and in vitro eosinophil chemotaxis and adhesion. Since eosinophils are proposed to have an important role in the pathophysiology of asthma and allergic disease, the effects of cetirizine on eosinophil function may be a mechanism of this agent's therapeutic regulation of the allergic reaction.
To determine the effect of cetirizine on in vitro eosinophil survival.
Using human eosinophils isolated from patients with allergic rhinitis, the cells were cultured in vitro for 48 to 72 hours with medium, cetirizine, or dexamethasone in the presence of IL-5, IL-3, or GM-CSF. Eosinophil survival was assessed by trypan blue exclusion.
In the presence of IL-5, but not GM-CSF or IL-3 100 microM cetirizine significantly inhibited eosinophil survival at 48 and 72 hours; the magnitude of this inhibition was dependent on cytokine concentration. Although cetirizine significantly suppressed cytokine promotion of eosinophil survival, it was not as potent as dexamethasone.
Although the in vitro concentration of cetirizine was required to be quite high, cetirizine may affect in vivo airway inflammation through its inhibition of IL-5-dependent eosinophil survival.
西替利嗪是一种抗组胺药,可抑制变应原激发后体内嗜酸性粒细胞流入炎症气道以及体外嗜酸性粒细胞的趋化性和黏附。由于嗜酸性粒细胞在哮喘和变应性疾病的病理生理学中被认为具有重要作用,西替利嗪对嗜酸性粒细胞功能的影响可能是该药物治疗性调节过敏反应的一种机制。
确定西替利嗪对体外嗜酸性粒细胞存活的影响。
使用从变应性鼻炎患者中分离出的人嗜酸性粒细胞,将细胞在白细胞介素-5(IL-5)、白细胞介素-3(IL-3)或粒细胞巨噬细胞集落刺激因子(GM-CSF)存在的情况下,与培养基、西替利嗪或地塞米松一起在体外培养48至72小时。通过台盼蓝排斥法评估嗜酸性粒细胞的存活情况。
在存在IL-5的情况下,但不存在GM-CSF或IL-3时,100微摩尔西替利嗪在48小时和72小时时显著抑制嗜酸性粒细胞存活;这种抑制程度取决于细胞因子浓度。虽然西替利嗪显著抑制细胞因子对嗜酸性粒细胞存活的促进作用,但其效力不如地塞米松。
虽然西替利嗪在体外所需的浓度相当高,但它可能通过抑制IL-5依赖的嗜酸性粒细胞存活来影响体内气道炎症。